CH659945A5 - Pharmazeutische anthralin-zusammensetzungen und verfahren zu ihrer herstellung. - Google Patents

Pharmazeutische anthralin-zusammensetzungen und verfahren zu ihrer herstellung. Download PDF

Info

Publication number: CH659945A5
Authority: CH; Switzerland
Prior art keywords: anthralin; weight; composition; composition according; water
Prior art date: 1983-06-09

Application number

CH2813/84A

Other languages

German (de)

English (en)

Inventor

Jonas C T Wang

Original Assignee

Bristol Myers Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1983-06-09

Filing date

1984-06-08

Publication date

1987-03-13

1984-06-08 Application filed by Bristol Myers Co filed Critical Bristol Myers Co

1987-03-13 Publication of CH659945A5 publication Critical patent/CH659945A5/de

Links

NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 title claims description 109
238000000034 method Methods 0.000 title claims description 17
239000008194 pharmaceutical composition Substances 0.000 title 1
229960002311 dithranol Drugs 0.000 claims description 108
239000000203 mixture Substances 0.000 claims description 95
239000004094 surface-active agent Substances 0.000 claims description 28
239000003945 anionic surfactant Substances 0.000 claims description 27
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 23
-1 sulfonyl fatty acids Chemical class 0.000 claims description 22
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 21
239000003963 antioxidant agent Substances 0.000 claims description 21
235000006708 antioxidants Nutrition 0.000 claims description 21
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 20
238000011282 treatment Methods 0.000 claims description 18
201000004681 Psoriasis Diseases 0.000 claims description 17
238000009472 formulation Methods 0.000 claims description 15
230000003078 antioxidant effect Effects 0.000 claims description 14
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 11
238000007254 oxidation reaction Methods 0.000 claims description 11
235000019333 sodium laurylsulphate Nutrition 0.000 claims description 11
239000004322 Butylated hydroxytoluene Substances 0.000 claims description 10
235000010323 ascorbic acid Nutrition 0.000 claims description 10
239000011668 ascorbic acid Substances 0.000 claims description 10
229960005070 ascorbic acid Drugs 0.000 claims description 10
235000010354 butylated hydroxytoluene Nutrition 0.000 claims description 10
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 10
229960004889 salicylic acid Drugs 0.000 claims description 10
239000008346 aqueous phase Substances 0.000 claims description 9
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
239000006071 cream Substances 0.000 claims description 9
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 claims description 8
230000006378 damage Effects 0.000 claims description 8
238000000354 decomposition reaction Methods 0.000 claims description 8
230000003647 oxidation Effects 0.000 claims description 8
229910019142 PO4 Inorganic materials 0.000 claims description 7
230000007794 irritation Effects 0.000 claims description 7
239000007787 solid Substances 0.000 claims description 7
239000002253 acid Substances 0.000 claims description 6
239000012071 phase Substances 0.000 claims description 6
235000021317 phosphate Nutrition 0.000 claims description 6
150000003254 radicals Chemical class 0.000 claims description 6
239000004255 Butylated hydroxyanisole Substances 0.000 claims description 5
235000019282 butylated hydroxyanisole Nutrition 0.000 claims description 5
235000014113 dietary fatty acids Nutrition 0.000 claims description 5
230000000694 effects Effects 0.000 claims description 5
239000000194 fatty acid Substances 0.000 claims description 5
229930195729 fatty acid Natural products 0.000 claims description 5
230000007774 longterm Effects 0.000 claims description 5
238000002360 preparation method Methods 0.000 claims description 5
206010040880 Skin irritation Diseases 0.000 claims description 4
150000008051 alkyl sulfates Chemical class 0.000 claims description 4
238000004128 high performance liquid chromatography Methods 0.000 claims description 4
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 4
239000002674 ointment Substances 0.000 claims description 4
231100000475 skin irritation Toxicity 0.000 claims description 4
230000036556 skin irritation Effects 0.000 claims description 4
150000003871 sulfonates Chemical class 0.000 claims description 4
230000000699 topical effect Effects 0.000 claims description 4
239000004264 Petrolatum Substances 0.000 claims description 3
150000004996 alkyl benzenes Chemical class 0.000 claims description 3
239000000539 dimer Substances 0.000 claims description 3
229940066842 petrolatum Drugs 0.000 claims description 3
235000019271 petrolatum Nutrition 0.000 claims description 3
OXLXSOPFNVKUMU-UHFFFAOYSA-N 1,4-dioctoxy-1,4-dioxobutane-2-sulfonic acid Chemical class CCCCCCCCOC(=O)CC(S(O)(=O)=O)C(=O)OCCCCCCCC OXLXSOPFNVKUMU-UHFFFAOYSA-N 0.000 claims description 2
230000002378 acidificating effect Effects 0.000 claims description 2
229940045714 alkyl sulfonate alkylating agent Drugs 0.000 claims description 2
150000008052 alkyl sulfonates Chemical class 0.000 claims description 2
238000002845 discoloration Methods 0.000 claims description 2
239000003814 drug Substances 0.000 claims description 2
239000000839 emulsion Substances 0.000 claims description 2
230000037311 normal skin Effects 0.000 claims description 2
229940056211 paraffin Drugs 0.000 claims description 2
239000012188 paraffin wax Substances 0.000 claims description 2
230000006641 stabilisation Effects 0.000 claims description 2
238000011105 stabilization Methods 0.000 claims description 2
239000000126 substance Substances 0.000 claims description 2
239000000047 product Substances 0.000 claims 8
QBPFLULOKWLNNW-UHFFFAOYSA-N chrysazin Chemical compound O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O QBPFLULOKWLNNW-UHFFFAOYSA-N 0.000 claims 6
238000004040 coloring Methods 0.000 claims 5
NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 3
CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 3
229940043253 butylated hydroxyanisole Drugs 0.000 claims 3
229940095259 butylated hydroxytoluene Drugs 0.000 claims 3
229960001577 dantron Drugs 0.000 claims 3
239000000543 intermediate Substances 0.000 claims 3
239000007764 o/w emulsion Substances 0.000 claims 3
206010015150 Erythema Diseases 0.000 claims 2
230000002682 anti-psoriatic effect Effects 0.000 claims 2
238000002512 chemotherapy Methods 0.000 claims 2
231100000321 erythema Toxicity 0.000 claims 2
239000011269 tar Substances 0.000 claims 2
CNJLMVZFWLNOEP-UHFFFAOYSA-N 4,7,7-trimethylbicyclo[4.1.0]heptan-5-one Chemical compound O=C1C(C)CCC2C(C)(C)C12 CNJLMVZFWLNOEP-UHFFFAOYSA-N 0.000 claims 1
206010022998 Irritability Diseases 0.000 claims 1
229940124091 Keratolytic Drugs 0.000 claims 1
206010067482 No adverse event Diseases 0.000 claims 1
VSSMJHUOAAZQMT-UHFFFAOYSA-N butanedioic acid;1-octylsulfonyloctane Chemical class OC(=O)CCC(O)=O.CCCCCCCCS(=O)(=O)CCCCCCCC VSSMJHUOAAZQMT-UHFFFAOYSA-N 0.000 claims 1
239000006227 byproduct Substances 0.000 claims 1
238000002144 chemical decomposition reaction Methods 0.000 claims 1
239000003246 corticosteroid Substances 0.000 claims 1
229960001334 corticosteroids Drugs 0.000 claims 1
235000005911 diet Nutrition 0.000 claims 1
230000037213 diet Effects 0.000 claims 1
238000006471 dimerization reaction Methods 0.000 claims 1
230000001530 keratinolytic effect Effects 0.000 claims 1
239000003410 keratolytic agent Substances 0.000 claims 1
229940100892 mercury compound Drugs 0.000 claims 1
150000002731 mercury compounds Chemical class 0.000 claims 1
125000000913 palmityl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
150000002978 peroxides Chemical class 0.000 claims 1
230000002265 prevention Effects 0.000 claims 1
239000000344 soap Substances 0.000 claims 1
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical group [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims 1
NGSFWBMYFKHRBD-UHFFFAOYSA-N sodium;2-hydroxypropanoic acid Chemical compound [Na+].CC(O)C(O)=O NGSFWBMYFKHRBD-UHFFFAOYSA-N 0.000 claims 1
230000000087 stabilizing effect Effects 0.000 claims 1
230000000475 sunscreen effect Effects 0.000 claims 1
239000000516 sunscreening agent Substances 0.000 claims 1
238000010998 test method Methods 0.000 claims 1
229940124597 therapeutic agent Drugs 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
238000004809 thin layer chromatography Methods 0.000 claims 1
229940126702 topical medication Drugs 0.000 claims 1
238000000870 ultraviolet spectroscopy Methods 0.000 claims 1
239000007762 w/o emulsion Substances 0.000 claims 1
239000000499 gel Substances 0.000 description 19
ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 14
150000002500 ions Chemical class 0.000 description 10
238000003756 stirring Methods 0.000 description 10
239000003921 oil Substances 0.000 description 9
239000002245 particle Substances 0.000 description 7
239000000473 propyl gallate Substances 0.000 description 7
235000010388 propyl gallate Nutrition 0.000 description 7
229940075579 propyl gallate Drugs 0.000 description 7
239000008213 purified water Substances 0.000 description 7
QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 6
239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 6
235000010385 ascorbyl palmitate Nutrition 0.000 description 6
239000002480 mineral oil Substances 0.000 description 6
235000010446 mineral oil Nutrition 0.000 description 6
MGYUQZIGNZFZJS-KTKRTIGZSA-N 2-[2-[(z)-octadec-9-enoxy]ethoxy]ethanol Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCOCCO MGYUQZIGNZFZJS-KTKRTIGZSA-N 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 4
DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
229940113096 isoceteth 20 Drugs 0.000 description 4
239000007788 liquid Substances 0.000 description 4
239000000693 micelle Substances 0.000 description 4
239000002736 nonionic surfactant Substances 0.000 description 4
229940099570 oleth-2 Drugs 0.000 description 4
238000004806 packaging method and process Methods 0.000 description 4
235000010267 sodium hydrogen sulphite Nutrition 0.000 description 4
239000000600 sorbitol Substances 0.000 description 4
238000001179 sorption measurement Methods 0.000 description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
125000000129 anionic group Chemical group 0.000 description 3
238000011156 evaluation Methods 0.000 description 3
238000002156 mixing Methods 0.000 description 3
229910052708 sodium Inorganic materials 0.000 description 3
239000011734 sodium Substances 0.000 description 3
QIGBRXMKCJKVMJ-UHFFFAOYSA-N Hydroquinone Chemical compound OC1=CC=C(O)C=C1 QIGBRXMKCJKVMJ-UHFFFAOYSA-N 0.000 description 2
229910052782 aluminium Inorganic materials 0.000 description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
150000001450 anions Chemical class 0.000 description 2
125000003289 ascorbyl group Chemical group [H]O[C@@]([H])(C([H])([H])O*)[C@@]1([H])OC(=O)C(O*)=C1O* 0.000 description 2
150000007942 carboxylates Chemical class 0.000 description 2
150000001768 cations Chemical class 0.000 description 2
125000000524 functional group Chemical group 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
239000011261 inert gas Substances 0.000 description 2
ZHALDANPYXAMJF-UHFFFAOYSA-N octadecanoate;tris(2-hydroxyethyl)azanium Chemical compound OCC[NH+](CCO)CCO.CCCCCCCCCCCCCCCCCC([O-])=O ZHALDANPYXAMJF-UHFFFAOYSA-N 0.000 description 2
150000003013 phosphoric acid derivatives Chemical class 0.000 description 2
238000012154 short term therapy Methods 0.000 description 2
229940001584 sodium metabisulfite Drugs 0.000 description 2
235000010262 sodium metabisulphite Nutrition 0.000 description 2
GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
150000003467 sulfuric acid derivatives Chemical class 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
229940029614 triethanolamine stearate Drugs 0.000 description 2
QIJRTFXNRTXDIP-UHFFFAOYSA-N (1-carboxy-2-sulfanylethyl)azanium;chloride;hydrate Chemical compound O.Cl.SCC(N)C(O)=O QIJRTFXNRTXDIP-UHFFFAOYSA-N 0.000 description 1
DYIOSHGVFJTOAR-JGWLITMVSA-N (2r,3r,4s,5r)-6-sulfanylhexane-1,2,3,4,5-pentol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)CS DYIOSHGVFJTOAR-JGWLITMVSA-N 0.000 description 1
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
ILCOCZBHMDEIAI-UHFFFAOYSA-N 2-(2-octadecoxyethoxy)ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCO ILCOCZBHMDEIAI-UHFFFAOYSA-N 0.000 description 1
JKXYOQDLERSFPT-UHFFFAOYSA-N 2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-[2-(2-octadecoxyethoxy)ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethoxy]ethanol Chemical compound CCCCCCCCCCCCCCCCCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCOCCO JKXYOQDLERSFPT-UHFFFAOYSA-N 0.000 description 1
WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
241000416162 Astragalus gummifer Species 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
CIWBSHSKHKDKBQ-DUZGATOHSA-N D-isoascorbic acid Chemical compound OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 description 1
241001277560 Galbula dea Species 0.000 description 1
229920001615 Tragacanth Polymers 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
QFUFIDWMZKCFNQ-UHFFFAOYSA-M [Na+].OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O Chemical compound [Na+].OC(=O)CC(O)(CC(O)=O)C(O)=O.CCCCCCCCCCCCOS([O-])(=O)=O QFUFIDWMZKCFNQ-UHFFFAOYSA-M 0.000 description 1
GKHOLUJNLGYFHA-UHFFFAOYSA-N [Na].CC(C)=O Chemical compound [Na].CC(C)=O GKHOLUJNLGYFHA-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001336 alkenes Chemical class 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
239000012736 aqueous medium Substances 0.000 description 1
239000012298 atmosphere Substances 0.000 description 1
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
239000000440 bentonite Substances 0.000 description 1
229910000278 bentonite Inorganic materials 0.000 description 1
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940082500 cetostearyl alcohol Drugs 0.000 description 1
238000006243 chemical reaction Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
239000002537 cosmetic Substances 0.000 description 1
239000008406 cosmetic ingredient Substances 0.000 description 1
229960001305 cysteine hydrochloride Drugs 0.000 description 1
230000002950 deficient Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
235000019329 dioctyl sodium sulphosuccinate Nutrition 0.000 description 1
YHAIUSTWZPMYGG-UHFFFAOYSA-L disodium;2,2-dioctyl-3-sulfobutanedioate Chemical compound [Na+].[Na+].CCCCCCCCC(C([O-])=O)(C(C([O-])=O)S(O)(=O)=O)CCCCCCCC YHAIUSTWZPMYGG-UHFFFAOYSA-L 0.000 description 1
229940080316 dried sodium phosphate Drugs 0.000 description 1
229940079593 drug Drugs 0.000 description 1
235000010350 erythorbic acid Nutrition 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
150000002170 ethers Chemical class 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
239000001257 hydrogen Substances 0.000 description 1
229910052739 hydrogen Inorganic materials 0.000 description 1
229960004337 hydroquinone Drugs 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
239000003112 inhibitor Substances 0.000 description 1
239000003999 initiator Substances 0.000 description 1
230000008863 intramolecular interaction Effects 0.000 description 1
238000011835 investigation Methods 0.000 description 1
229940026239 isoascorbic acid Drugs 0.000 description 1
239000010410 layer Substances 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
229940057995 liquid paraffin Drugs 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000002609 medium Substances 0.000 description 1
229910021645 metal ion Inorganic materials 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229960002900 methylcellulose Drugs 0.000 description 1
PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012454 non-polar solvent Substances 0.000 description 1
GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 1
229940066429 octoxynol Drugs 0.000 description 1
229920002113 octoxynol Polymers 0.000 description 1
JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-O oxonium Chemical compound [OH3+] XLYOFNOQVPJJNP-UHFFFAOYSA-O 0.000 description 1
239000001301 oxygen Substances 0.000 description 1
229910052760 oxygen Inorganic materials 0.000 description 1
229940023569 palmate Drugs 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000002798 polar solvent Substances 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
XWGJFPHUCFXLBL-UHFFFAOYSA-M rongalite Chemical compound [Na+].OCS([O-])=O XWGJFPHUCFXLBL-UHFFFAOYSA-M 0.000 description 1
238000000926 separation method Methods 0.000 description 1
235000010413 sodium alginate Nutrition 0.000 description 1
239000000661 sodium alginate Substances 0.000 description 1
229940005550 sodium alginate Drugs 0.000 description 1
HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
229940057950 sodium laureth sulfate Drugs 0.000 description 1
235000010265 sodium sulphite Nutrition 0.000 description 1
AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
235000019345 sodium thiosulphate Nutrition 0.000 description 1
SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
DAJSVUQLFFJUSX-UHFFFAOYSA-M sodium;dodecane-1-sulfonate Chemical compound [Na+].CCCCCCCCCCCCS([O-])(=O)=O DAJSVUQLFFJUSX-UHFFFAOYSA-M 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
229940098760 steareth-2 Drugs 0.000 description 1
150000005846 sugar alcohols Polymers 0.000 description 1
BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
239000002344 surface layer Substances 0.000 description 1
OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
229940035024 thioglycerol Drugs 0.000 description 1
235000010487 tragacanth Nutrition 0.000 description 1
239000000196 tragacanth Substances 0.000 description 1
229940116362 tragacanth Drugs 0.000 description 1
238000010792 warming Methods 0.000 description 1
239000000230 xanthan gum Substances 0.000 description 1
235000010493 xanthan gum Nutrition 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
229940082509 xanthan gum Drugs 0.000 description 1
GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Dermatology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

CH2813/84A 1983-06-09 1984-06-08 Pharmazeutische anthralin-zusammensetzungen und verfahren zu ihrer herstellung. CH659945A5 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US50285283A	1983-06-09	1983-06-09

Publications (1)

Publication Number	Publication Date
CH659945A5 true CH659945A5 (de)	1987-03-13

Family

ID=23999686

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH2813/84A CH659945A5 (de)	1983-06-09	1984-06-08	Pharmazeutische anthralin-zusammensetzungen und verfahren zu ihrer herstellung.

Country Status (21)

Country	Link
JP (1)	JPS608222A (fr)
AT (1)	AT393959B (fr)
AU (1)	AU569085B2 (fr)
BE (1)	BE899874A (fr)
CH (1)	CH659945A5 (fr)
CY (1)	CY1531A (fr)
DE (1)	DE3421510A1 (fr)
DK (1)	DK163028C (fr)
ES (1)	ES8707107A1 (fr)
FI (1)	FI83837C (fr)
FR (1)	FR2547725B1 (fr)
GB (1)	GB2142534B (fr)
HK (1)	HK66490A (fr)
IE (1)	IE57562B1 (fr)
IT (1)	IT1183058B (fr)
LU (1)	LU85411A1 (fr)
NO (1)	NO171623C (fr)
NZ (1)	NZ208338A (fr)
OA (1)	OA07720A (fr)
PT (1)	PT78713A (fr)
SE (1)	SE465205B (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0322197A1 (fr) *	1987-12-22	1989-06-28	Drythanol Ltd.	Compositions du dithranol

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4551480A (en) *	1983-06-21	1985-11-05	Stiefel Laboratories, Inc.	Compositions for the treatment of psoriasis
DE3413569A1 (de) *	1984-04-11	1985-10-24	Röhm Pharma GmbH, 6108 Weiterstadt	Pharmazeutisches mittel zur psoriasis-therapie
AT408067B (de) *	1995-03-17	2001-08-27	Gebro Pharma Gmbh	Pharmazeutische zusammensetzung zur topischen applizierung und verfahren zu ihrer herstellung

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1070949A (en) *	1964-10-16	1967-06-07	Hyman Yarrow	Topical compositions for the treatment of psoriasis
GB1574090A (en) *	1977-07-06	1980-09-03	Drythanol Ltd	Dithranol composition for the treatment of psoriasis
DE3008805A1 (de) *	1980-03-07	1981-09-24	Paul 8501 Oberasbach Unger	Skibremse
CA1179271A (fr) *	1981-10-23	1984-12-11	Jean-Francois Grollier	Composition epaissie anhydre, stable a l'oxydation, a base d'anthraline ou de l'un de ses derives dans un support constitue d'un alkyl ester d'acide gras et d'un agent epaississant, et son utilisation dans le traitement des maladies de la peau
FR2520233A1 (fr) *	1982-01-28	1983-07-29	Oreal	Composition d'anthraline ou de l'un de ses derives dans un ester aromatique et son utilisation dans le traitement des maladies de la peau
FR2526321A1 (fr) *	1982-05-10	1983-11-10	Salomon & Fils F	Frein de ski

1984
- 1984-05-31 NZ NZ208338A patent/NZ208338A/en unknown
- 1984-06-04 FR FR8408718A patent/FR2547725B1/fr not_active Expired
- 1984-06-06 FI FI842274A patent/FI83837C/fi not_active IP Right Cessation
- 1984-06-06 ES ES533186A patent/ES8707107A1/es not_active Expired
- 1984-06-08 DE DE19843421510 patent/DE3421510A1/de not_active Withdrawn
- 1984-06-08 NO NO842326A patent/NO171623C/no unknown
- 1984-06-08 DK DK283884A patent/DK163028C/da not_active IP Right Cessation
- 1984-06-08 AU AU29237/84A patent/AU569085B2/en not_active Ceased
- 1984-06-08 IE IE1440/84A patent/IE57562B1/en not_active IP Right Cessation
- 1984-06-08 BE BE0/213108A patent/BE899874A/fr not_active IP Right Cessation
- 1984-06-08 AT AT0189784A patent/AT393959B/de not_active IP Right Cessation
- 1984-06-08 PT PT78713A patent/PT78713A/pt not_active IP Right Cessation
- 1984-06-08 GB GB08414653A patent/GB2142534B/en not_active Expired
- 1984-06-08 LU LU85411A patent/LU85411A1/fr unknown
- 1984-06-08 CH CH2813/84A patent/CH659945A5/de not_active IP Right Cessation
- 1984-06-08 JP JP59116766A patent/JPS608222A/ja active Pending
- 1984-06-08 OA OA58314A patent/OA07720A/fr unknown
- 1984-06-08 IT IT21331/84A patent/IT1183058B/it active
- 1984-06-08 SE SE8403110A patent/SE465205B/sv not_active IP Right Cessation
1990
- 1990-08-23 HK HK664/90A patent/HK66490A/xx unknown
- 1990-11-16 CY CY1531A patent/CY1531A/en unknown

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0322197A1 (fr) *	1987-12-22	1989-06-28	Drythanol Ltd.	Compositions du dithranol

Also Published As

Publication number	Publication date
FI842274L (fi)	1984-12-10
JPS608222A (ja)	1985-01-17
HK66490A (en)	1990-08-31
NO171623C (no)	1993-04-21
FR2547725B1 (fr)	1987-12-04
FR2547725A1 (fr)	1984-12-28
NO171623B (no)	1993-01-04
OA07720A (fr)	1985-08-30
IE841440L (en)	1984-12-09
DK163028C (da)	1992-06-09
GB2142534A (en)	1985-01-23
SE465205B (sv)	1991-08-12
IE57562B1 (en)	1992-12-16
DK283884D0 (da)	1984-06-08
PT78713A (en)	1984-07-01
FI83837C (fi)	1991-09-10
DK163028B (da)	1992-01-13
GB8414653D0 (en)	1984-07-11
LU85411A1 (fr)	1985-03-26
FI842274A0 (fi)	1984-06-06
AU569085B2 (en)	1988-01-21
SE8403110L (sv)	1984-12-10
SE8403110D0 (sv)	1984-06-08
NO842326L (no)	1984-12-10
DE3421510A1 (de)	1984-12-20
AU2923784A (en)	1984-12-13
AT393959B (de)	1992-01-10
GB2142534B (en)	1987-06-03
BE899874A (fr)	1984-12-10
ES533186A0 (es)	1987-07-16
NZ208338A (en)	1987-11-27
ES8707107A1 (es)	1987-07-16
DK283884A (da)	1984-12-10
ATA189784A (de)	1991-07-15
FI83837B (fi)	1991-05-31
IT1183058B (it)	1987-10-05
CY1531A (en)	1990-11-16
IT8421331A0 (it)	1984-06-08

Legal Events

Date	Code	Title	Description
1995-02-28	PL	Patent ceased
2024-10-31	PL	Patent ceased

Publication	Publication Date	Title
DE2418345C2 (de)	1985-04-25	Pharmazeutisches Mittel für äußerliche Anwendung an menschlicher Haut
AT390372B (de)	1990-04-25	Verwendung von solarfiltern zur stabilisierung und verbesserung der hautvertraeglichkeit von benzoylperoxyd enthaltenden zubereitungen zur lokalen aknebehandlung
DE3125710C2 (fr)	1988-09-22
DE3783683T2 (de)	1993-05-19	Hautpenetration verbessernde zusammensetzungen.
DE60216634T2 (de)	2007-09-27	Gel mit mindestens einem retinoid und benzoylperoxid
DE3875128T2 (de)	1993-04-29	Mikroemulsionen.
DE69535184T2 (de)	2007-08-23	Stabile Gelzusammensetzung zur topischen Behandlung von Hautkrankheiten
DE69522696T2 (de)	2002-04-18	Nimesulid zur aüsserlichen anwendung
DE3382637T2 (de)	1993-04-22	Eine lipidloesliche substanz enthaltende waessrige fluessigkeit.
DE3751761T2 (de)	1996-09-19	Penetrationsverbesserer für die transdermale Verabreichung von systemisch wirksamen Arzneimitteln
DE2707878C2 (de)	1986-01-30	Verwendung von Mono- und/oder Diglyceriden mittelkettiger Fettsäuren
DE69319480T2 (de)	1998-11-12	Badepräparat
DE3246081A1 (de)	1984-06-14	Nitroglycerin-spray
DE3302739C2 (fr)	1991-01-24
DE3239183C2 (fr)	1990-12-13
DE2557615A1 (de)	1977-06-23	Neue niclosamid-suspensionsformulierungen
DE2608221B1 (de)	1977-07-21	Kosmetisches mittel zur glaettung der haut
DE3705894A1 (de)	1987-08-27	Pharmazeutische zusammensetzungen
DE2601489C2 (fr)	1990-02-01
DE2818827C2 (de)	1983-10-27	Mittel zur Behandlung von Psoriasis
DE3411225C2 (fr)	1991-11-07
DE69402259T2 (de)	1997-07-24	Zusammensetzungen enthaltend 8-Hydroxychinolin zur Behandlung hyperproliferativer Hautkrankheiten
CH659945A5 (de)	1987-03-13	Pharmazeutische anthralin-zusammensetzungen und verfahren zu ihrer herstellung.
DE69031569T2 (de)	1998-02-19	Podophyllotoxinzubereitung enthaltend triglyceride
DE68907755T2 (de)	1994-03-10	Mittel zur Verhinderung der Ergrauung der Haare und Repigmentierung ergrauter Haare.

CH659945A5 - Pharmazeutische anthralin-zusammensetzungen und verfahren zu ihrer herstellung. - Google Patents

Info

Links

Classifications

Landscapes

Applications Claiming Priority (1)

Publications (1)

Family

ID=23999686

Family Applications (1)

Country Status (21)

Cited By (1)

Families Citing this family (3)

Family Cites Families (6)

Cited By (1)

Also Published As

Similar Documents

Legal Events